Personal information

Verified email addresses

Activities

Works (14)

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

Clinical Cancer Research
2024-07-15 | Journal article
Contributors: Christie P.M. Verkleij; Chloe A. O’Neill; Marloes E.C. Broekmans; Kristine A. Frerichs; Wassilis S.C. Bruins; Carolien Duetz; Sandy Kruyswijk; Serena R. Baglio; Sheri Skerget; Rocio Montes de Oca et al.
Source: check_circle
Crossref

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

HemaSphere
2023-05 | Journal article
Contributors: Verkleij CPM; Frerichs KA; Broekmans MEC; Duetz C; O'Neill CA; Bruins WSC; Homan-Weert PM; Minnema MC; Levin MD; Broijl A et al.
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Blood Advances
2021-04-27 | Journal article
Contributors: Christie P. M. Verkleij; Marloes E. C. Broekmans; Mark van Duin; Kristine A. Frerichs; Rowan Kuiper; A. Vera de Jonge; Martin Kaiser; Gareth Morgan; Amy Axel; Rengasamy Boominathan et al.
Source: check_circle
Crossref

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.

Cancers
2020-12 | Journal article
Contributors: Verkleij CPM; Jhatakia A; Broekmans MEC; Frerichs KA; Zweegman S; Mutis T; Bezman NA; van de Donk NWCJ
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.

Oncotarget
2020-11 | Journal article
Contributors: Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.

Clinical cancer research : an official journal of the American Association for Cancer Research
2020-01 | Journal article
Contributors: Frerichs KA; Broekmans MEC; Marin Soto JA; van Kessel B; Heymans MW; Holthof LC; Verkleij CPM; Boominathan R; Vaidya B; Sendecki J et al.
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma

Nature Communications
2019-04-04 | Journal article
Contributors: Tim van Groningen; Nurdan Akogul; Ellen M. Westerhout; Alvin Chan; Nancy E. Hasselt; Danny A. Zwijnenburg; Marloes Broekmans; Peter Stroeken; Franciska Haneveld; Gerrit K. J. Hooijer et al.
Source: check_circle
Crossref

Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients.

European journal of cancer (Oxford, England : 1990)
2019-02 | Journal article
Contributors: Verly IRN; Leen R; Meinsma JR; Hooijer GKJ; Savci-Heijink CD; van Nes J; Broekmans M; Wanders RJA; van Kuilenburg ABP; Tytgat GAM
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.

Expert review of clinical immunology
2018-02 | Journal article
Contributors: Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C et al.
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Clinical cancer research : an official journal of the American Association for Cancer Research
2017-10 | Journal article
Contributors: Krejcik J; Frerichs KA; Nijhof IS; van Kessel B; van Velzen JF; Bloem AC; Broekmans MEC; Zweegman S; van Meerloo J; Musters RJP et al.
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

Nature genetics
2017-06 | Journal article
Contributors: van Groningen T; Koster J; Valentijn LJ; Zwijnenburg DA; Akogul N; Hasselt NE; Broekmans M; Haneveld F; Nowakowska NE; Bras J et al.
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Proceedings of the National Academy of Sciences of the United States of America
2012-10 | Journal article
Contributors: Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Nature genetics
2012-10 | Journal article
Contributors: Molenaar JJ; Domingo-Fernández R; Ebus ME; Lindner S; Koster J; Drabek K; Mestdagh P; van Sluis P; Valentijn LJ; van Nes J et al.
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central

Anti-human vascular endothelial growth factor (VEGF) antibody selection for immunohistochemical staining of proliferating blood vessels.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
2010-02 | Journal article
Contributors: van der Loos CM; Meijer-Jorna LB; Broekmans ME; Ploegmakers HP; Teeling P; de Boer OJ; van der Wal AC
Source: Self-asserted source
Marloes Broekmans via Europe PubMed Central